INTRODUCTION {#s1}
============

Coronary heart disease (CHD) is a major cause of death and disability worldwide \[[@R1]\]. The incidence of CHD is higher in males than females. In China, moreover, the prevalence of CHD is increasing. One large study from the U.S. puts the annual mortality rate due to CHD there at 5% among males and 3.65% among females \[[@R2]\]. CHD is characterized by remodeling and narrowing of the coronary arteries, which supply blood, and thus oxygen, to the heart \[[@R3]\]. Twins study has shown that heritable factors account for 30-60% of inter-individual variation in the risk of CHD \[[@R4]\], which means genetic factors are key to an individual\'s susceptibility to CHD.

Various genomic regions and gene polymorphisms have been identified as being associated with the risk of CHD \[[@R5]--[@R7]\]. To date, genome-wide association studies (GWAS) have identified more than 40 common variants associated with the risk of CHD \[[@R8], [@R9]\]. For example, *PPAP2B* encodes lipid phosphate phosphatase 3 (LPP3), which is required for vascular development and may also contribute to the pathogenesis of human atherosclerotic disease \[[@R10]\]. A previous study showed that the rs17114046 single nucleotide polymorphism (SNP) in the final intron of *PPAP2B* is associated with an increased risk of CHD in Europeans and South Asians \[[@R11]\]. Another recent study observed that the CHD protective A allele of rs72664324 at the *PPAP2B* locus increases the transcriptional enhancer response to oxidized low-density lipoprotein in macrophages, which results in an alteration in LPP3 activity, and in turn promotes increased metabolism of pro-inflammatory mediators within atherosclerosis lesions \[[@R12]\].

The abovementioned studies suggest genetic polymorphisms in *PPAP2B* are closely associated with the risk of CHD. On the other hand, little is known about the contribution of *PPAP2B* SNPs to gender-related differences in CHD risk, especially in the Chinese Han population. We therefore performed a case-control study to investigate the associations between *PPAP2B* SNPs and the risk of CHD in Chinese Han males and females.

RESULTS {#s2}
=======

We recruited 456 cases (291 males and 165 females; average age at diagnosis: 59.56, 64.01) and 685 controls (385 males and 300 females; average age: 47.55, 49.93) for this study. The characteristics of the cases and controls are shown in Table [1](#T1){ref-type="table"}. We divided the samples into male and female subgroups, and multivariate analyses were adjusted for age.

###### Basic characteristics of CHD cases and healthy controls

  Variables            Male            Female                                                 
  -------------------- --------------- -------------- ---------- -------------- ------------- ----------
  Number               291             385                       165            300           
  Age yr (mean ± sd)   59.56±12.18     47.55±10.655   \< 0.001   64.01±10.74    49.93±7.743   \< 0.001
  ALB (g/L)            40.86±4.50                                41.13±0.30                   
  ALB/GLOB             1.66±0.26                                 1.59±0.01                    
  ALT (U/L)            32.32±34.17                               29.09±4.61                   
  AST (U/L)            38.16±69.46                               33.32±3.49                   
  AST/ALT              1.23±0.94                                 1.42±0.08                    
  aPOA1 (g/L)          1.22±0.24                                 1.33±0.02                    
  aPOB (g/L)           0.97±0.37                                 1.05±0.03                    
  aPOA1/aPOB           1.45±0.71                                 1.47±0.06                    
  Ca(mmol/l)           2.29±0.16                                 2.29±0.01                    
  GGT (U/L)            47.06±69.30                               40.39±7.46                   
  GLU (mmol/L)         6.27±2.23                                 6.45±0.21                    
  HDL-C (mmol/L)       1.10±0.25                                 1.19±0.02                    
  LDL-C (mmol/L)       1.86±0.89                                 2.02±0.57                    
  Lp(a) (mg/L)         227.16±253.31                             260.70±19.93                 
  MPV (fl)             13.27±7.29                                12.75±0.59                   
  PLT (109/L)          163.19±72.13                              180.38±0.29                  
  PCT (%)              1.25±3.45                                 0.94±0.22                    
  PDW (%)              14.32±2.79                                14.07±0.26                   
  TP(g/L)              69.51±6.63                                67.229±0.455                 
  TG (mmol/L)          1.80±1.65                                 1.80±0.10                    
  TC (mmol/L)          3.96±1.19                                 4.33±0.09                    
  UA(umol/l)           311.77±85.46                              265.80±6.24                  

ALB: albumin, ALB/GLOB: albumin/globulin, ALT: alanine aminotransferase, AST: aspartate aminotransferase, apoA: apolipoprotein A, apoB: apolipoprotein B, GGT: gamma-glutamyl transpeptidase, GLU: glucose, HDL: high-density lipoprotein, LDL: low-density lipoprotein, LP(a): lipoprotein, MPV: Mean Platelet Volume, PLT: platelet, PCT: plateletcrit, PDW: platelet distribution width, TP: total protein, TG: triglyceride, TC: total cholesterol, UA: Uric acid.

*p* values were calculated using the Welch\'s test; *p* \< 0.001 indicates statistical significance.

A total of five *PPAP2B* SNPs were identified in the cases and controls. All SNP call rates exceeded 98.2%, which was considered high enough to perform association analyses. In the controls, all SNPs were in Hardy-Weinberg equilibrium (HWE) (Table [2](#T2){ref-type="table"}). For SNP rs1759752, the allele frequency distributions differed between male cases and controls. (*p* = 0.015, OR: 1.401, 95%CI: 1.066-1.481), whereas there was no significant difference in the female subgroup. We also compared the genotype frequencies between cases and controls. For SNP rs1759752, the genotype frequency distributions also differed between the male cases and controls (*p* = 0.019), while for rs12566304, the genotype frequency distributions differed between female cases and controls (*p* = 0.020) (Table [3](#T3){ref-type="table"}).

###### Allele frequencies in cases and controls and odds ratio estimates for CHD

  SNP ID        Gene(s)   Band     Alleles A^a^/B   MAF     HWE*p*   ORs      95% CI   *p*           
  ------------- --------- -------- ---------------- ------- -------- -------- -------- ------------- ---------
  Male                                                                                               
   rs11206831   PPAP2B    1p32.2   T/C              0.050   0.055    1        0.909    0.559-1.478   0.700
   rs1759752    PPAP2B    1p32.2   C/G              0.220   0.168    0.8558   1.401    1.066-1.841   0.015\*
   rs1930760    PPAP2B    1p32.2   T/C              0.490   0.467    0.4733   1.093    0.881-1.356   0.418
   rs12566304   PPAP2B    1p32.2   A/C              0.132   0.148    0.1561   0.877    0.643-1.198   0.410
   rs914830     PPAP2B    1p32.2   T/C              0.324   0.329    0.8172   0.976    0.776-1.229   0.838
  Female                                                                                             
   rs11206831   PPAP2B    1p32.2   T/C              0.050   0.045    1        1.011    0.530-1.928   0.975
   rs1759752    PPAP2B    1p32.2   C/G              0.209   0.165    1        1.338    0.950-1.883   0.094
   rs1930760    PPAP2B    1p32.2   T/C              0.442   0.498    0.7299   0.799    0.610-1.046   0.102
   rs12566304   PPAP2B    1p32.2   A/C              0.161   0.148    0.1653   1.099    0.759-1.591   0.619
   rs914830     PPAP2B    1p32.2   T/C              0.339   0.348    0.1621   0.961    0.724-1.246   0.784

MAF, minor allelic frequency; HWE, Hardy-Weinberg Equilibrium; ORs, odds ratios; CI: confidence interval.

^a^ Minor allele; \**p* ≤ 0.05 indicates statistical significance;

###### Genotype distribution for SNPs in CHD patients and healthy controls

  SNP ID       Alleles A^a^/B   Genotype   Male (No.)   *p*^b^   Female (No.)   *p*^b^         
  ------------ ---------------- ---------- ------------ -------- -------------- -------- ----- ---------
  rs11206831   T/C              CC         262          344      0.942          150      273   1
                                TC         29           40                      15       27    
                                TT         0            1                       0        0     
  rs1759752    C/G              GG         172          205      0.019\*        103      209   0.246
                                CG         110          106                     55       83    
                                CC         9            11                      7        8     
  rs1930760    T/C              CC         76           105      0.607          55       77    0.208
                                TC         145          199                     74       147   
                                TT         70           80                      36       76    
  rs12566304   A/C              CC         223          283      0.624          120      214   0.020\*
                                AC         59           90                      37       83    
                                AA         9            12                      8        3     
  rs914830     T/C              CC         130          174      0.765          69       133   0.240
                                TC         132          167                     80       125   
                                TT         28           43                      16       42    

^a^ Minor alleles, OR: Odds ratio, CI: Confidence interval.

^b^: *p* values were calculated from Pearson\'s chi-square test adjusted for age.

\* *p* ≤ 0.05 indicates statistical significance.

We assumed the minor allele of each SNP was a CHD risk factor compared to the wild-type allele and analyzed associations between SNPs and CHD in various inheritance models (Table [4](#T4){ref-type="table"}). In the male subgroup, rs1759752 was associated with an increased CHD risk in the dominant model (*p* = 0.035, OR: 1.47, 95%CI: 1.03-2.11) and overdominant model (*p* = 0.045, OR: 1.46, 95%CI: 1.01-2.11). In the female subgroup, rs12566304 was associated with a decreased CHD risk in the codominant model (*p* = 0.038, OR: 0.57, 95%CI: 0.32-1.00) and overdominant model (*p* = 0.031, OR: 0.54, 95%CI: 0.31-0.96).

###### Association between significant SNPs and CHD in multiple inheritance models (adjusted for age)

  SNP                   Model          Genotype   Group=case    Group=control   OR (95% CI)         *p*       AIC     BIC
  --------------------- -------------- ---------- ------------- --------------- ------------------- --------- ------- -------
  rs1759752in Male      Codominant     G/G        172 (59.1%)   265 (69.4%)     1                   0.11      760.6   778.6
                                       G/C        110 (37.8%)   106 (27.8%)     1.48 (1.02-2.15)                      
                                       C/C        9 (3.1%)      11 (2.9%)       1.40 (0.51-3.79)                      
                        Dominant       G/G        172 (59.1%)   265 (69.4%)     1                   0.035\*   758.6   772.2
                                       G/C-C/C    119 (40.9%)   117 (30.6%)     1.47 (1.03-2.11)                      
                        Recessive      G/G-G/C    282 (96.9%)   371 (97.1%)     1                   0.69      762.9   776.4
                                       C/C        9 (3.1%)      11 (2.9%)       1.22 (0.45-3.30)                      
                        Overdominant   G/G-C/C    181 (62.2%)   276 (72.2%)     1                   0.045\*   759     772.6
                                       G/C        110 (37.8%)   106 (27.8%)     1.46 (1.01-2.11)                      
                        Log-additive   ---        ---           ---             1.37 (1.00-1.88)    0.049     759.2   772.7
  rs12566304in Female   Codominant     C/C        120 (72.7%)   214 (71.3%)     1                   0.038\*   411.9   428.5
                                       C/A        37 (22.4%)    83 (27.7%)      0.57 (0.32-1.00)                      
                                       A/A        8 (4.8%)      3 (1%)          2.83 (0.60-13.46)                     
                        Dominant       C/C        120 (72.7%)   214 (71.3%)     1                   0.14      414.2   426.6
                                       C/A-A/A    45 (27.3%)    86 (28.7%)      0.67 (0.39-1.15)                      
                        Recessive      C/C-C/A    157 (95.2%)   297 (99%)       1                   0.11      413.9   426.3
                                       A/A        8 (4.8%)      3 (1%)          3.32 (0.71-15.53)                     
                        Overdominant   C/C-A/A    128 (77.6%)   217 (72.3%)     1                   0.031\*   411.8   424.2
                                       C/A        37 (22.4%)    83 (27.7%)      0.54 (0.31-0.96)                      
                        Log-additive   ---        ---           ---             0.84 (0.53-1.33)    0.45      415.8   428.3

ORs, odds ratios; CI: confidence interval; AIC: Akaike\'s Information criterion; BIC: Bayesian Information criterion.

\* *p* ≤0.05 indicates statistical significance.

The basic characteristics of the study subjects stratified by genotype are shown in Table [5](#T5){ref-type="table"}. In the male subgroup, we found significant differences in the albumin (ALB), apolipoprotein A (aPOA1) and total protein (TP) concentrations, as well as the alanine aminotransferase (ALT)/aspartate aminotransferase (AST) ratio among differnet *PPAP2B* rs1759752 genotypes (*p* \< 0.05). Subjects carrying the rs1759752 "CC" genotype had lower ALB, aPOA1 and TP concentrations and higher AST/ALT ratios than those carrying the "CG" and "GG" genotypes. In the female subgroup, we observed a significant difference in gamma-glutamyl transpeptidase (GGT) concentrations among the *PPAP2B* rs12566304 genotypes (*p* \< 0.05). Patients who carried the minor C allele displayed lower GGT levels than those with the wild-type A allele.

###### Clinical and biochemical characteristics of participants, stratified based on *PPAP2B* gene polymorphism

  SNP                   Characteristics   Genotypes (mean ± sd)   *p*                     
  --------------------- ----------------- ----------------------- --------------- ------- --
  rs1759752in Male                        CC                      CG              GG      
  ALB                   37.14±5.63        40.56±4.52              41.26±4.35      0.019   
  AST/ALT               1.87±1.77         1.37±1.20               1.11±0.63       0.011   
  aPOA1                 1.02±0.16         1.20±0.22               1.24±0.25       0.014   
  TP                    60.22±8.33        65.45±6.58              66.53±6.42      0.010   
  rs12566304in Female                     CC                      AC              AA      
  GGT                   34.21±62.98       33.83±36.38             159.63±335.72   0.001   

ALB: albumin, ALB/GLOB: albumin/globulin, ALT: alanine aminotransferase, AST: aspartate aminotransferase, apoA: apolipoprotein A, GGT: gamma-glutamyl transpeptidase, HDL: high-density lipoprotein, TP: total protein, UA: Uric acid.

*p* ≤0.05 indicates statistical significance.

In the male subgroup, haplotype analysis revealed two blocks in *PPAP2B* (Figure [1](#F1){ref-type="fig"}): block 1 included rs1759752 and rs1930760, while block 2 included rs12566304 and rs914830. Further analyses of associations between *PPAP2B* haplotypes and CHD risk showed that haplotype "GC" in block 1 was protective against CHD in males (*p* = 0.03, OR: 0.76, 95%CI: 0.59 - 0.97) (Table [6](#T6){ref-type="table"}).

![Haplotype block map for all the SNPs of the *PPAP2B* gene](oncotarget-08-13166-g001){#F1}

###### *PPAP2B* haplotype frequencies and the association with the risk of CHD in male case and control patients (adjusted for age)

  Block   SNP                    Haplotypes   Freq-case            Freq-control   OR (95% CI)   *p*
  ------- ---------------------- ------------ -------------------- -------------- ------------- -----
  1       rs1759752\|rs1930760   GT           0.484                0.464          1             ---
  GC      0.296                  0.369        0.76 (0.59 - 0.97)   0.03\*                       
  CC      0.215                  0.164        1.28 (0.95 - 1.74)   0.11                         

\* *p* ≤0.05 indicates statistical significance.

DISCUSSION {#s3}
==========

In the present case-control study, we investigated the association between five *PPAP2B* SNPs and the risk of CHD in the Chinese Han population. We found that SNP rs1759752 is associated with an increased risk of CHD in males, while rs12566304 is associated with a decreased risk of CHD in females. Additionally, we observed that haplotype "GC" of rs1759752 and rs1930760 was protective against CHD in males.

CHD was once considered as a cholesterol storage disease, but is now known to reflect complex interactions among molecular messages within the cells of the artery wall and in the blood \[[@R13]\]. Mammals express three lipid phosphate phosphatases (LPPs): LPP1, LPP2 and LPP3 encoded by *PPAP2A*, *PPAP2C* and *PPAP2B*, respectively. In mice, loss of *PPAP2A* \[[@R14]\] or inactivation of *PPAP2C* \[[@R15]\] does not result in phenotypic alteration. However, *PPAP2B* knockout is embryonically lethal, mainly due to defects in extra-embryonic vascular development \[[@R10]\], which suggests *PPAP2B* plays an important role in vascular development.

*PPAP2B* is located at locus 1p32.2. It is abundantly expressed in human plaque foam cells, and its specific enzymatic activity in macrophages was increased by oxidized low-density lipoprotein \[[@R12]\]. In our study, we found that males who carried the rs1759752 "CC" genotype had lower ALB, aPOA1and TP concentrations and a higher AST/ALT ratio than those carrying the "CG" or "GG" genotype. In addition, female patients who carried the minor C allele of rs12566304 displayed lower GGT levels than those carrying the wild-type A allele. It is noteworthy, that lower ALB, aPOA1, TP and GGT levels, which may reflect increased proteinase activity, and higher AST/ALT ratios are always associated with both liver and cardiovascular disease. We therefore suggest that *PPAP2B* rs1759752 and rs12566304 SNPs may affect CHD risk by influencing LPP3 enzymatic activity.

Earlier GWAS studies revealed several common variants that influence CHD risk in populations of European ancestry. These include rs1333049, rs599839, rs3008621, rs501120, rs6922269 and rs2943634, among others \[[@R16]\]. Chinese researchers have replicated these studies to explore novel loci in the Chinese population, including rs6903956, rs2123536, rs1842896, rs9268402 and rs7136259 \[[@R17]--[@R19]\]. In the present study, we showed that rs1759752 is associated with increased CHD risk in males, while rs12566304 is associated with decreased CHD risk in females.

The present study has several potential limitations. First, the sample size is relatively small, and the participants included only Chinese population. Second, CHD is a very heterogeneous disease with many traditional risk factors, including tobacco use, physical inactivity, poor nutrition, obesity, hypertension, high blood cholesterol, and diabetes. We could not completely eliminate the potential influences of these factors on the results.

In sum, our results indicate that *PPAP2B* rs1759752 is associated with an increased risk of CHD in males, while rs12566304 was associated with a decreased risk of CHD in females. These SNPs may have the potentially to serve as prognostic biomarkers for CHD among the Chinese Han population. Further study will focus on determining the functional role of these SNPs and on validating our findings with a larger sample.

MATERIALS AND METHODS {#s4}
=====================

Ethics statement {#s4_1}
----------------

We strictly obeyed the World Medical Association Declaration of Helsinki when using human tissue and discussing the study protocol with subjects. The protocol was approved by the Ethical Committee of the Seventh People\'s Hospital of Zhengzhou. Each participant provided written, informed consent.

Subjects {#s4_2}
--------

All participants in our study were Han Chinese lived in Henan Province. A total of 456 CHD patients and 685 healthy controls were consecutively recruited between May 2013 and July 2015 in the Seventh People\'s Hospital of Zhengzhou, China. Patients were diagnosed with CHD using standard coronary angiography, which revealed ≥ 70% stenosis of the main branch of a coronary artery or aortic stenosis ≥ 50%. Subjects with myocardial infarction, stable angina and unstable angina were classified as CHD subjects. There were no age, sex or disease-stage classification restrictions when enrolling the case group. Excluded were subjects with chronic diseases or conditions involving the brain, liver, heart or lung, and patients with more advanced cardiovascular, metabolic or endocrine diseases. Controls were healthy people receiving physical examinations in other clinical departments of Tangdu Hospital. Healthy controls did not have congenital heart disease, familial hypercholesterolemia, end-stage renal disease or vasculitis, which could have affected our study results. Peripheral blood was collected from both cases and controls for DNA extraction.

Clinical data and patient demographics {#s4_3}
--------------------------------------

A standardized epidemiological questionnaire was provided to all subjects to collect basic demographic information, including sex, age, residence, educational status, history of family cancer, history of smoking and alcohol consumption. Plasma carcinoembryonic antigen and alpha-fetoprotein levels were determined to ensure that no controls suffered from any cancer.

SNP selection and genotyping {#s4_4}
----------------------------

Candidate *PPAP2B* SNPs were selected from previous publications that associated polymorphisms with CHD \[[@R20], [@R21]\]. SNPs with minor allele frequencies (MAF) \> 5% in the HapMap CHB population were selected. We validated five SNPs in *PPAP2B*. A GoldMag-Mini Purification Kit (GoldMag Co. Ltd. Xian city, China) was used to extract genomic DNA from whole blood samples. DNA concentrations were measured using a DU530 UV/VIS spectrophotometer (Beckman Instruments, Fullerton, CA, USA). Using MassARRAY Assay Design 3.0 software (Sequenom, San Diego, CA, USA), we designed a multiplexed SNP MassEXTENDED assay \[[@R22]\]. SNPs were genotyped using the standard protocol recommended by the MassARRAY RS1000 (Sequenom) manufacturer, and data were analyzed using Typer 4.0 Software (Sequenom). The primers used for this study were listed in Table [7](#T7){ref-type="table"}.

###### Primers used for this study

  SNP_ID       1st_PCRP                         2st_PCRP                         UEP_SEQ
  ------------ -------------------------------- -------------------------------- ----------------------------
  rs11206831   ACGTTGGATGTGACCTCACTGAGTCTGAAC   ACGTTGGATGAGGCAGGAACTATGCCTGTG   ccTCCTCACACCTTTGCAAGT
  rs1759752    ACGTTGGATGTCAGGGAGTCGACAACACAG   ACGTTGGATGGGGTTAGGATTACAAGAAGC   tagtATTACAAGAAGCCAAGTCCG
  rs1930760    ACGTTGGATGGCACTGGCTCAAGTTAACTG   ACGTTGGATGTTTAAACTCCAGGCTATTGC   gaggTTGATGAAATTAGTTACCTAGC
  rs12566304   ACGTTGGATGGAATGTTGGCACTGACAATG   ACGTTGGATGTCTCCTTATTCCCATGTGAC   ggttaATGTGACTGAGGATGAAACA
  rs914830     ACGTTGGATGGGAGACGACTTTTACTGAGC   ACGTTGGATGTCTTGGCCTGTACTTGAGTG   gTGAGTGGGTCTGGGCGT

UEP: Unextended mini-sequencing primer.

Statistical analysis {#s4_5}
--------------------

We used the Microsoft Excel and SPSS 17.0 (SPSS, Chicago, IL) statistical packages to perform the statistical analyses. All *p* values were two-sided, and *p* \< 0.05 was considered statistically significant. A *t* test and Chi-squared test were performed to compare sex and age differences between cases and controls. Fisher\'s exact test was applied to each SNP in the controls to test for departure from the Hardy-Weinberg Equilibrium (HWE). Odds ratios (ORs) and 95% confidence intervals (CIs) for the allele and genotype frequencies were calculated using the Pearson Chi-square test adjusted for age (sex subgroups were separated) \[[@R23]\]. The Cochran-Armitage trend test was used to determine associations between SNPs and CHD.

PLINK software (<http://pngu.mgh.harvard.edu/purcell/plink/>) was used to assess SNP associations with CHD risk in different genetic models (Codominant, dominant, recessive, overdominat and additive). We used unconditional logistic regression analysis to calculate ORs and 95% CIs adjusted for age \[[@R24]\]. Pairwise linkage disequilibrium and haplotype constructions were performed using HAPLOVIEW 4.1 (<http://broad.mit.edu/mpg/haploview>) \[[@R25]\].
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